Why the study?
HCN channels are important drug targets, but few known compounds are able to discriminate among HCN channel isoforms.
EC18 is a novel HCN4-preferring channel blocker that can serve as a pharmacological tool to study the physiological and pathological roles of HCN4 channels in cardiac and neuronal tissues.
EC18 offers first HCN4-preferring tool; extends isoform research but leaves clinical translation open.
Hyperpolarization-activated cyclic nucleotide-gated (HCN) channels are membrane proteins encoded by four genes (HCN1–4) and widely distributed in the central and peripheral nervous system and in the heart. HCN channels are involved in several physiological functions, including the generation of rhythmic activity, and are considered important drug targets if compounds with isoform selectivity are developed. At present, however, few compounds are known, which are able to discriminate among HCN channel isoforms. The inclusion of the three-methylene chain of zatebradine into a cyclohexane ring gave a compound ( 3a ) showing a 5-fold preference for HCN4 channels, and ability to selectively modulate I h in different tissues. Compound 3a has been tested for its ability to reduce I h and to interact with other ion channels in the heart and the central nervous system. Its preference for HCN4 channels makes this compound useful to elucidate the contribution of this isoform in the physiological and pathological processes involving hyperpolarization-activated current.
No takes yet. Share an insight, caveat, or question.
Romanelli et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: